DEFB4A: A Potential Drug Target and Biomarker (G1673)

Target Name: DEFB4A

NCBI ID: G1673

DEFB4A: A Potential Drug Target and Biomarker

DEFB4A, short for doublecortin-like peptide 4A, is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the potential of DEFB4A as a drug target and biomarker, and discuss its potential clinical applications.

Potential Drug Target

DEFB4A has been shown to play a role in several cellular processes that are important for cell survival and proliferation. It is a key regulator of the cell cycle, and has been shown to promote the growth and survival of various cell types. It is also involved in the regulation of cell adhesion and migration, and has been shown to play a role in the development of cancer.

One of the key features of DEFB4A that makes it an attractive drug target is its ability to interact with several different signaling pathways. It has been shown to interact with multiple signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. This makes it a potentially versatile target for drug development.

In addition, DEFB4A has been shown to play a role in the regulation of cellular stress responses. It has been shown to reduce cellular stress in response to various stressors, including ionizing radiation and chemotherapy drugs. This may make it an attractive target for the development of anti-stress drugs.

Potential Biomarker

DEFB4A has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a biomarker makes it an attractive target for the development of diagnostic tests and therapeutic approaches.

In cancer, DEFB4A has been shown to be involved in the regulation of cell cycle progression, and has been shown to promote the growth and survival of various cancer cell types. This makes it an potential target for the development of anti-cancer drugs.

In neurodegenerative diseases, DEFB4A has been shown to play a role in the regulation of cellular stress responses and has been shown to promote the development of neurodegeneration. This makes it an potential target for the development of neurodegenerative disease therapies.

In autoimmune disorders, DEFB4A has been shown to play a role in the regulation of immune cell function and has been shown to contribute to the development of autoimmune disorders. This makes it an potential target for the development of autoimmune disease therapies.

Conclusion

In conclusion, DEFB4A is a protein that has been shown to play a role in several cellular processes that are important for cell survival and proliferation. Its potential as a drug target and biomarker makes it an attractive target for the development of new therapies for a variety of diseases. Further research is needed to fully understand the role of DEFB4A in cellular processes and its potential as a drug target and biomarker.

Protein Name: Defensin Beta 4A

Functions: Exhibits antimicrobial activity against Gram-negative bacteria and Gram-positive bacteria, with highest activity against Gram-negative bacteria (PubMed:9202117, PubMed:10837369). Antimicrobial activity against P.aruginosa seems to be salt-sensitive and is reduced with high salt concentrations greater than 25 mM (PubMed:10837369). Also exhibits antimicrobial activity against the yeast C.albicans (PubMed:9202117, PubMed:10837369, PubMed:30050988). Permeabilizes C.albicans cell membranes via targeting plasma membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2), thereby leading to cell fragmentation and cell death (PubMed:30050988). Acts as a ligand for C-C chemokine receptor CCR6 (PubMed:10521347, PubMed:20068036). Binds to CCR6 and induces chemotactic activity of CCR6-expressing cells, such as immature dendritic cells and memory T cells (PubMed:10521347, PubMed:20068036)

More Common Targets